The Norwegian cancer drug development company Clavis Pharma, announced that it had received orphan drug designation from the US Food & Drug Administration, for the treatment of pancreatic cancer.

Last year, Clavis Pharma was granted an equivalent designation from the European Commission, and these designations will be of great help for Clavis Pharma in the further development of a treatment for pancreatic cancer.

Read more


 

More news

(2011-12-21)
(2011-07-08)
(2011-02-28)
(2010-12-21)
(2010-11-30)
(2010-11-26)
(2010-11-22)
(2010-09-20)
(2010-06-17)
(2010-03-19)
(2009-08-21)
(2007-05-09)
 
 
News type
 
 

Latest PE Voice

Harald Mix on Nordic private equity

- 1/10/2012 10:10:00 AM
At the Argentum Conference in 2010, we asked Harald Mix, Managing Partner and Co-founder of Altor Equity Partners about the outlook for future returns in Nordic private equity.
 
 

Calendar

2012-02-16 in Bergen

Vestlandskonferansen

2012-02-27 in Berlin

SuperReturn International 2012

2012-03-05 in Copenhagen

Nordic Fundraising Summit

2012-03-14 in Geneva

EVCA Investors' Forum

2012-03-15 in La Clusaz

EVCA Networking Event 2012
 
Copyright Argentum 2009